John Simard to retire as CEO of XBiotech, biopharmaceutical company focused on developing True Human monoclonal antibodies.

Tuesday, Dec 9, 2025 9:13 am ET1min read
XBIT--

John Simard, CEO of XBiotech Inc., a biopharmaceutical company, is retiring. The company specializes in True Human monoclonal antibodies for treating various diseases such as rheumatology, infectious diseases, cardiovascular disease, and cancer. Their True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The company has several candidate products, including Natrunix, a clinical-stage therapeutic for MRSA, and several pre-clinical-stage therapeutics.

John Simard to retire as CEO of XBiotech, biopharmaceutical company focused on developing True Human monoclonal antibodies.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet